S. Chiara

550 total citations
22 papers, 400 citations indexed

About

S. Chiara is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Chiara has authored 22 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Reproductive Medicine and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Chiara's work include Colorectal Cancer Treatments and Studies (9 papers), Ovarian cancer diagnosis and treatment (9 papers) and Cancer Treatment and Pharmacology (7 papers). S. Chiara is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Ovarian cancer diagnosis and treatment (9 papers) and Cancer Treatment and Pharmacology (7 papers). S. Chiara collaborates with scholars based in Italy, Australia and United Kingdom. S. Chiara's co-authors include Pierfranco Conté, Milena Bruzzone, I. Brunetti, F Carnino, Angiolo Gadducci, Antonella Romanini, Alfredo Falcone, A. Rubagotti, Lazzaro Repetto and Nicola Ragni and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Gynecologic Oncology.

In The Last Decade

S. Chiara

22 papers receiving 377 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Chiara Italy 11 232 184 176 83 69 22 400
E.J. Aartsen Netherlands 10 175 0.8× 166 0.9× 131 0.7× 105 1.3× 63 0.9× 13 385
Carolin Kümper Germany 8 135 0.6× 79 0.4× 126 0.7× 109 1.3× 32 0.5× 14 383
María Jesús Rubio Spain 16 506 2.2× 344 1.9× 180 1.0× 214 2.6× 69 1.0× 48 693
C. Madroñal Spain 4 446 1.9× 176 1.0× 153 0.9× 254 3.1× 88 1.3× 11 533
C. Coens Netherlands 3 624 2.7× 271 1.5× 155 0.9× 344 4.1× 83 1.2× 6 673
H D Homesley United States 9 468 2.0× 335 1.8× 163 0.9× 218 2.6× 55 0.8× 12 611
Giuseppe Laurelli Italy 11 289 1.2× 89 0.5× 68 0.4× 377 4.5× 41 0.6× 18 523
David L. Marchetti United States 12 171 0.7× 68 0.4× 75 0.4× 138 1.7× 54 0.8× 12 293
Paul C. Tseng United States 7 200 0.9× 72 0.4× 96 0.5× 140 1.7× 36 0.5× 9 342
Susan S. Robey-Cafferty United States 11 71 0.3× 209 1.1× 164 0.9× 26 0.3× 142 2.1× 13 405

Countries citing papers authored by S. Chiara

Since Specialization
Citations

This map shows the geographic impact of S. Chiara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Chiara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Chiara more than expected).

Fields of papers citing papers by S. Chiara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Chiara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Chiara. The network helps show where S. Chiara may publish in the future.

Co-authorship network of co-authors of S. Chiara

This figure shows the co-authorship network connecting the top 25 collaborators of S. Chiara. A scholar is included among the top collaborators of S. Chiara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Chiara. S. Chiara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cremolini, Chiara, Fotios Loupakis, Gianluca Masi, et al.. (2016). FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Annals of Oncology. 27(5). 843–849. 43 indexed citations
2.
3.
Sobrero, Alberto, Stephen P. Ackland, Stephen Clarke, et al.. (2007). 3060 POSTER Final data from a large phase II trial of first-line bevacizumab plus classic or modified FOLFIRI in metastatic colorectal cancer (CRC). European Journal of Cancer Supplements. 5(4). 254–254. 2 indexed citations
4.
5.
Falcone, Alfredo, M. Andreuccetti, I. Brunetti, et al.. (2007). Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer (MCRC). Journal of Clinical Oncology. 25(18_suppl). 4026–4026. 4 indexed citations
6.
Falcone, Alfredo, M. Andreuccetti, Cinzia Orlandini, et al.. (2007). Randomized phase III study of FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) vs FOLFIRI (irinotecan and 5FU/LV) as first-line treatment of metastatic colorectal cancer (MCRC): Subgroup and multivariate analysis. CINECA IRIS Institutial research information system (University of Pisa). 2 indexed citations
7.
8.
Falcone, Alfredo, Gianluca Masi, Giovanni Benedetti, et al.. (2006). Biweekly irinotecan, oxaliplatin, and infusional 5-FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized, phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.). CINECA IRIS Institutial research information system (University of Pisa). 18 indexed citations
9.
Sobrero, Alberto, Stephen P. Ackland, S. Chiara, et al.. (2006). Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer. Journal of Clinical Oncology. 24(18_suppl). 3544–3544. 9 indexed citations
10.
Mancini, Sérgio, et al.. (2001). Physiological tissue changes after administration of micronized Diosmin/Hesperidin, individually or in association with Endermologie®. 1 indexed citations
11.
12.
Conté, Pierfranco, Milena Bruzzone, F Carnino, et al.. (1996). High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.. Journal of Clinical Oncology. 14(2). 351–356. 69 indexed citations
13.
Vigani, Antonella, S. Chiara, Loredana Miglietta, et al.. (1991). Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: Potentiation of mitoxantrone cytotoxicity. Gynecologic Oncology. 41(1). 52–55. 10 indexed citations
14.
Bruzzone, Milena, Elisabetta Campora, S. Chiara, et al.. (1990). CA-125 monitoring in the management of ovarian cancer.. PubMed. 10(5A). 1353–9. 6 indexed citations
15.
Bruzzone, Milena, Lazzaro Repetto, S. Chiara, et al.. (1990). Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecologic Oncology. 38(3). 392–395. 44 indexed citations
16.
Repetto, Lazzaro, S. Chiara, Serafina Mammoliti, et al.. (1990). Crossover study with cisplatin or carboplatin in advanced ovarian cancer. Gynecologic Oncology. 39(2). 146–149. 5 indexed citations
17.
Bruzzone, Milena, Pierfranco Conté, Michael Ruvolo, et al.. (1989). Evaluation of the Ovarian Cancer Antigen, CA-125, as a Tumor Marker. Oncology. 46(2). 117–122. 7 indexed citations
18.
Chiara, S., G Foglia, Franco Odicino, et al.. (1988). Uterine Sarcomas: A Clinicopathologic Study. Oncology. 45(6). 428–433. 13 indexed citations
19.
Falcone, Alfredo, S. Chiara, P. Franzone, et al.. (1988). Moving-Strip Abdomino-Pelvic Radiotherapy After cis-Platinum-Based Chemotherapy and Second-Look Operation A Feasibility Study in Advanced Ovarian Cancer. American Journal of Clinical Oncology. 11(1). 16–20. 8 indexed citations
20.
Falcone, Alfredo, S. Chiara, P. Franzone, et al.. (1988). Moving-Strip Abdomino-Pelvic Radiotherapy After Cis-Platinum-Based Chemotherapy and Second-Look Operation. Medical dosimetry. 13(3). 161–161. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E.J. Aartsen Breakdown of academic impact, for papers by Carolin Kümper Breakdown of academic impact, for papers by María Jesús Rubio Breakdown of academic impact, for papers by C. Madroñal Breakdown of academic impact, for papers by C. Coens Breakdown of academic impact, for papers by H D Homesley Breakdown of academic impact, for papers by Giuseppe Laurelli Breakdown of academic impact, for papers by David L. Marchetti Breakdown of academic impact, for papers by Paul C. Tseng Breakdown of academic impact, for papers by Susan S. Robey-Cafferty
Rankless by CCL
2026